A review of treatment options employed in relapsed/refractory AML

References

• Döhner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345–1377. doi:10.1182/blood.2022016867.
   PubMed Web of Science ®Google Scholar
• Shah A, Andersson TM, Rachet B, et al. Survival and cure of acute myeloid leukaemia in England, 1971-2006: a population-based study. Br J Haematol. 2013 Aug;162(4):509–16. doi:10.1111/bjh.12425.
   PubMed Web of Science ®Google Scholar
• Appelbaum FR, Gundacker H, Head DR, et al. Age and acute myeloid leukemia. Blood. 2006 May 1;107(9):3481–5. doi:10.1182/blood-2005-09-3724.
   PubMed Web of Science ®Google Scholar
• Thol F, Ganser A. Treatment of relapsed acute myeloid leukemia. Curr Treat Options Oncol. 2020 Jun 29;21(8):66), doi:10.1007/s11864-020-00765-5.
   PubMed Web of Science ®Google Scholar
• Thol F, Schlenk RF, Heuser M, et al. How I treat refractory and early relapsed acute myeloid leukemia. Blood. 2015;126(3):319–327. doi:10.1182/blood-2014-10-551911.
   PubMed Web of Science ®Google Scholar
• Short NJ, Zhou S, Fu C, et al. Association of measurable residual disease with survival outcomes in patients with acute myeloid leukemia: a systematic review and meta-analysis. JAMA Oncol. 2020 Dec 1;6(12):1890–1899. doi:10.1001/jamaoncol.2020.4600.
   PubMed Web of Science ®Google Scholar
• Terwijn M, van Putten WL, Kelder A, et al. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study. J Clin Oncol. 2013 Nov 1;31(31):3889–97. doi:10.1200/JCO.2012.45.9628.
   PubMed Web of Science ®Google Scholar
• McMahon CM, Ferng T, Canaani J, et al. Clonal selection with RAS pathway activation mediates secondary clinical resistance to selective FLT3 inhibition in acute myeloid leukemia. Cancer Discov. 2019 Aug;9(8):1050–1063. doi:10.1158/2159-8290.CD-18-1453.
   PubMed Web of Science ®Google Scholar
• Intlekofer AM, Shih AH, Wang B, et al. Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations. Nature. 2018 Jul;559(7712):125–129. doi:10.1038/s41586-018-0251-7.
   PubMed Web of Science ®Google Scholar
• D'Souza A, Fretham C, Lee SJ, et al. Current use of and trends in hematopoietic cell transplantation in the United States. Biol Blood Marrow Transplant. 2020 Aug;26(8):e177–e182. doi:10.1016/j.bbmt.2020.04.013. Epub 2020 May 11. Erratum in: Transplant Cell Ther. 2022 Oct;28(10):715–716.
   PubMed Web of Science ®Google Scholar
• Jan JC, Blaise D. Hematopoietic stem cell transplantation for patients with AML in first complete remission. Blood. 2016;127(1):62–70. doi: 10.1182/blood-2015-07-604546.
   PubMed Web of Science ®Google Scholar
• Faruqi A, Cytarabine TP. (Updated 2022 Aug 12). In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK557680/.
   Google Scholar
• Gandhi V, Estey E, Keating MJ, et al. Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. J Clin Oncol. 1993 Jan;11(1):116–24. doi:10.1200/JCO.1993.11.1.116.
   PubMed Web of Science ®Google Scholar
• Sen K, Kalaycio M. Evan's syndrome precipitated by fludarabine therapy in a case of CLL. Am J Hematol. 1999 Jul;61(3):219), doi:10.1002/(sici)1096-8652(199907)61:3<219::aid-ajh15>3.0.co;2-#.
   PubMed Web of Science ®Google Scholar
• Faderl S, Gandhi V, O'Brien S, et al. Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood. 2005 Feb 1;105(3):940–7. doi:10.1182/blood-2004-05-1933.
   PubMed Web of Science ®Google Scholar
• Martin MG, Welch JS, Hladnik AK, et al. Cladribine in the treatment of acute myeloid leukemia: a single-institution experience. Clin Lymphoma Myeloma. 2009 Aug;9(4):298–301. doi:10.3816/CLM.2009.n.058.
   PubMedGoogle Scholar
• Coufal N, Farnaes L. Anthracyclines and anthracenediones. In: Minev B, editor. Cancer management in man: chemotherapy, biological therapy, hyperthermia and supporting measures. cancer growth and progression, Vol. 13. Dordrecht: Springer; 2011. doi:10.1007/978-90-481-9704-0_5
   Google Scholar
• Cresteil T. Aclarubicin. Reference Module in Biomedical Sciences. 2017. doi:10.1016/b978-0-12-801238-3.97571-8
   Google Scholar
• Montecucco A, Zanetta F, Biamonti G. Molecular mechanisms of etoposide. EXCLI J. 2015 Jan 19;14:95–108. doi:10.17179/excli2015-561.
   PubMed Web of Science ®Google Scholar
• Liu F, Knight T, Su Y, et al. Venetoclax synergistically enhances the anti-leukemic activity of vosaroxin against acute myeloid leukemia cells Ex vivo. Target Oncol. 2019 Jun;14(3):351–364. doi:10.1007/s11523-019-00638-4.
   PubMed Web of Science ®Google Scholar
• Wetzler M, Segal D. Omacetaxine as an anticancer therapeutic: what is old is new again. Curr Pharm Des. 2011;17(1):59–64. doi:10.2174/138161211795049778.
   PubMed Web of Science ®Google Scholar
• Chao SH, Fujinaga K, Marion JE, et al. Flavopiridol inhibits P-TEFb and blocks HIV-1 replication. J Biol Chem. 2000;275(37):28345–8. doi:10.1074/jbc.C000446200.
   PubMed Web of Science ®Google Scholar
• Ferguson P, Hills RK, Grech A, et al. An operational definition of primary refractory acute myeloid leukemia allowing early identification of patients who may benefit from allogeneic stem cell transplantation. Haematologica. 2016 Nov;101(11):1351–1358. doi:10.3324/haematol.2016.148825.
   PubMed Web of Science ®Google Scholar
• Herzig RH, Lazarus HM, Wolff SN, et al. High-dose cytosine arabinoside therapy with and without anthracycline antibiotics for remission reinduction of acute nonlymphoblastic leukemia. J Clin Oncol. 1985 Jul;3(7):992–7. doi:10.1200/JCO.1985.3.7.992.
   PubMed Web of Science ®Google Scholar
• Karanes C, Kopecky KJ, Head DR, et al. A phase III comparison of high dose ARA-C (HIDAC) versus HIDAC plus mitoxantrone in the treatment of first relapsed or refractory acute myeloid leukemia southwest oncology group study. Leuk Res. 1999 Sep;23(9):787–94. doi:10.1016/s0145-2126(99)00087-9.
   PubMed Web of Science ®Google Scholar
• Löwenberg B. Sense and nonsense of high-dose cytarabine for acute myeloid leukemia. Blood. 2013;121(1):26–28. doi:10.1182/blood-2012-07-444851.
   PubMed Web of Science ®Google Scholar
• Bashir Y, Geelani S, Bashir N, et al. Role of low dose cytarabine in elderly patients with acute myeloid leukemia: an experience. South Asian J Cancer. 2015 Jan-Mar;4(1):4–6. doi:10.4103/2278-330X.149918.
   PubMedGoogle Scholar
• Pastore D, Specchia G, Carluccio P, et al. FLAG-IDA in the treatment of refractory/relapsed acute myeloid leukemia: single-center experience. Ann Hematol. 2003 Apr;82(4):231–5. doi:10.1007/s00277-003-0624-2.
   PubMed Web of Science ®Google Scholar
• Virchis A, Koh M, Rankin P, et al. Fludarabine, cytosine arabinoside, granulocyte-colony stimulating factor with or without idarubicin in the treatment of high risk acute leukaemia or myelodysplastic syndromes. Br J Haematol. 2004 Jan;124(1):26–32. doi:10.1046/j.1365-2141.2003.04728.x.
   PubMed Web of Science ®Google Scholar
• Milligan DW, Wheatley K, Littlewood T, et al. Fludarabine and cytosine are less effective than standard ADE chemotherapy in high-risk acute myeloid leukemia, and addition of G-CSF and ATRA are not beneficial: results of the MRC AML-HR randomized trial. Blood. 2006 Jun 15;107(12):4614–22. doi:10.1182/blood-2005-10-4202.
   PubMed Web of Science ®Google Scholar
• Ho AD, Lipp T, Ehninger G, et al. Combination of mitoxantrone and etoposide in refractory acute myelogenous leukemia–an active and well-tolerated regimen. J Clin Oncol. 1988 Feb;6(2):213–7. doi:10.1200/JCO.1988.6.2.213.
   PubMed Web of Science ®Google Scholar
• Amadori S, Arcese W, Isacchi G, et al. Mitoxantrone, etoposide, and intermediate-dose cytarabine: an effective and tolerable regimen for the treatment of refractory acute myeloid leukemia. J Clin Oncol. 1991 Jul;9(7):1210–4. doi:10.1200/JCO.1991.9.7.1210.
   PubMed Web of Science ®Google Scholar
• Sternberg DW, Aird W, Neuberg D, et al. Treatment of patients with recurrent and primary refractory acute myelogenous leukemia using mitoxantrone and intermediate-dose cytarabine: a pharmacologically based regimen. Cancer. 2000 May 1;88(9):2037–41. doi:10.1002/(sici)1097-0142(20000501)88:9<2037::aid-cncr8>3.0.co;2-k.
   PubMed Web of Science ®Google Scholar
• De Astis E, Clavio M, Raiola AM, et al. Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemia. Ann Hematol. 2014 Dec;93(12):2011–8. doi:10.1007/s00277-014-2143-8.
   PubMed Web of Science ®Google Scholar
• Litzow MR, Wang XV, Carroll MP, et al. A randomized trial of three novel regimens for recurrent acute myeloid leukemia demonstrates the continuing challenge of treating this difficult disease. Am J Hematol. 2019 Jan;94(1):111–117. doi:10.1002/ajh.25333.
   PubMed Web of Science ®Google Scholar
• Martin MG, Welch JS, Hladnik AK, et al. Cladribine in the treatment of acute myeloid leukemia: a single-institution experience. Clin Lymphoma Myeloma. 2009 Aug;9(4):298–301. doi:10.3816/CLM.2009.n.058.
   PubMedGoogle Scholar
• Wierzbowska A, Robak T, Pluta A, et al. Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukemia Group. Eur J Haematol. 2008 Feb;80(2):115–26. doi:10.1111/j.1600-0609.2007.00988.x.
   PubMed Web of Science ®Google Scholar
• Yu W, Mao L, Qian J, et al. Homoharringtonine in combination with cytarabine and aclarubicin in the treatment of refractory/relapsed acute myeloid leukemia: a single-center experience. Ann Hematol. 2013 Aug;92(8):1091–100. doi:10.1007/s00277-013-1758-5.
   PubMed Web of Science ®Google Scholar
• Brown RA, Herzig RH, Wolff SN, et al. High-dose etoposide and cyclophosphamide without bone marrow transplantation for resistant hematologic malignancy. Blood. 1990 Aug 1;76(3):473–9.
   PubMed Web of Science ®Google Scholar
• Roboz GJ, Rosenblat T, Arellano M, et al. International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed/refractory acute myeloid leukemia. J Clin Oncol. 2014 Jun 20;32(18):1919–26. doi:10.1200/JCO.2013.52.8562.
   PubMed Web of Science ®Google Scholar
• Ravandi F, Ritchie EK, Sayar H, et al. Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study. Lancet Oncol. 2015 Sep;16(9):1025–1036. doi:10.1016/S1470-2045(15)00201-6.
   PubMed Web of Science ®Google Scholar
• Lancet JE, Uy GL, Cortes JE, et al. CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. J Clin Oncol. 2018 Sep 10;36(26):2684–2692. doi:10.1200/JCO.2017.77.6112.
   PubMed Web of Science ®Google Scholar
• Zeidner JF, Foster MC, Blackford AL, et al. Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia. Haematologica. 2015 Sep;100(9):1172–9. doi:10.3324/haematol.2015.125849.
   PubMed Web of Science ®Google Scholar
• Dombret H, Seymour JF, Butrym A, et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood. 2015 Jul 16;126(3):291–9. doi:10.1182/blood-2015-01-621664.
   PubMed Web of Science ®Google Scholar
• Robles C, Kim KM, Oken MM, et al. Low-dose cytarabine maintenance therapy vs observation after remission induction in advanced acute myeloid leukemia: an eastern cooperative oncology group trial (E5483). Leukemia. 2000 Aug;14(8):1349–53. doi:10.1038/sj.leu.2401850.
   PubMed Web of Science ®Google Scholar
• Agarwal SK, DiNardo CD, Potluri J, et al. Management of venetoclax-posaconazole interaction in acute myeloid leukemia patients: evaluation of dose adjustments. Clin Ther. 2017 Feb;39(2):359–367. doi:10.1016/j.clinthera.2017.01.003.
   PubMed Web of Science ®Google Scholar
• Kordella C, Lamprianidou E, Kotsianidis I. Mechanisms of action of hypomethylating agents: endogenous retroelements at the epicenter. Frontiers in Oncology. March 9, 2021;11:650473. doi:10.3389/fonc.2021.650473.
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Stein EM, de Botton S, et al. Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML. N Engl J Med. 2018 Jun 21;378(25):2386–2398. doi:10.1056/NEJMoa1716984.
   PubMed Web of Science ®Google Scholar
• Stein EM, DiNardo CD, Pollyea DA, et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood. 2017 Aug 10;130(6):722–731. doi:10.1182/blood-2017-04-779405.
   PubMed Web of Science ®Google Scholar
• Larrosa-Garcia M, Baer MR. FLT3 inhibitors in acute myeloid leukemia: current status and future directions. Mol Cancer Ther. 2017 Jun;16(6):991–1001. doi:10.1158/1535-7163.MCT-16-0876.
   PubMed Web of Science ®Google Scholar
• Fiskus W, Boettcher S, Daver N, et al. Effective menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c). Blood Cancer J. 2022 Jan 11;12(1):5), doi:10.1038/s41408-021-00603-3.
   PubMed Web of Science ®Google Scholar
• Johnstone RW, Licht JD. Histone deacetylase inhibitors in cancer therapy. Cancer Cell. July 2003;4(1):13–18. doi:10.1016/S1535-6108(03)00165-X.
   PubMed Web of Science ®Google Scholar
• Cortes J, Feldman E, Yee K, et al. Two dosing regimens of tosedostat in elderly patients with relapsed or refractory acute myeloid leukaemia (OPAL): a randomised open-label phase 2 study. Lancet Oncol. 2013 Apr;14(4):354–62. doi:10.1016/S1470-2045(13)70037-8.
   PubMed Web of Science ®Google Scholar
• Advani AS, Elson P, Kalaycio ME, … Sekeres MA. Bortezomib+ MEC (mitoxantrone, etoposide, cytarabine) for relapsed/refractory acute myeloid leukemia: final results of an expanded phase 1 trial. Blood. 2014;124(21):978.
   Web of Science ®Google Scholar
• Park S, Chapuis N, Saint Marcoux F, et al. A phase Ib GOELAMS study of the mTOR inhibitor RAD001 in association with chemotherapy for AML patients in first relapse. Leukemia. 2013 Jul;27(7):1479–86. doi:10.1038/leu.2013.17.
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020 Aug 13;383(7):617–629. doi:10.1056/NEJMoa2012971.
   PubMed Web of Science ®Google Scholar
• Labrador J, Saiz-Rodríguez M, de Miguel D, et al. Use of venetoclax in patients with relapsed or refractory acute myeloid leukemia: The PETHEMA registry experience. Cancers. 2022;14:1734. doi:10.3390/cancers14071734.
   PubMed Web of Science ®Google Scholar
• Wang YW, Tsai CH, Lin CC, et al. Cytogenetics and mutations could predict outcome in relapsed and refractory acute myeloid leukemia patients receiving BCL-2 inhibitor venetoclax. Ann Hematol. 2020 Mar;99(3):501–511. doi:10.1007/s00277-020-03911-z.
   PubMed Web of Science ®Google Scholar
• Konopleva M, Pollyea DA, Potluri J, et al. Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Discov. 2016 Oct;6(10):1106–1117. doi:10.1158/2159-8290.CD-16-0313.
   PubMed Web of Science ®Google Scholar
• Ivanoff S, Gruson B, Chantepie SP, et al. 5-Azacytidine treatment for relapsed or refractory acute myeloid leukemia after intensive chemotherapy. Am J Hematol. 2013 Jul;88(7):601–5. doi:10.1002/ajh.23464.
   PubMed Web of Science ®Google Scholar
• Ritchie EK, Feldman EJ, Christos PJ, et al. Decitabine in patients with newly diagnosed and relapsed acute myeloid leukemia. Leuk Lymphoma. 2013 Sep;54(9):2003–7. doi:10.3109/10428194.2012.762093.
   PubMed Web of Science ®Google Scholar
• Marcucci G, Maharry K, Wu YZ, et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. J Clin Oncol. 2010 May 10;28(14):2348–55. doi:10.1200/JCO.2009.27.3730.
   PubMed Web of Science ®Google Scholar
• Montesinos P, Recher C, Vives S, et al. Ivosidenib and azacitidine in IDH1-mutated acute myeloid leukemia. N Engl J Med. 2022 Apr 21;386(16):1519–1531. doi:10.1056/NEJMoa2117344.
   PubMed Web of Science ®Google Scholar
• Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016 Jun 9;374(23):2209–2221. doi:10.1056/NEJMoa1516192.
   PubMed Web of Science ®Google Scholar
• Stone RM, Mandrekar SJ, Sanford BL, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017 Aug 3;377(5):454–464. doi:10.1056/NEJMoa1614359.
   PubMed Web of Science ®Google Scholar
• Daver N, Schlenk RF, Russell NH, et al. Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia. 2019 Feb;33(2):299–312. doi:10.1038/s41375-018-0357-9.
   PubMed Web of Science ®Google Scholar
• Perl AE, Martinelli G, Cortes JE, et al. Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML. N Engl J Med. 2019 Oct 31;381(18):1728–1740. doi:10.1056/NEJMoa1902688.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Khaled S, Martinelli G, et al. Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2019 Jul;20(7):984–997. doi:10.1016/S1470-2045(19)30150-0.
   PubMed Web of Science ®Google Scholar
• Usuki K, Handa H, Choi I, et al. Safety and pharmacokinetics of quizartinib in Japanese patients with relapsed or refractory acute myeloid leukemia in a phase 1 study. Int J Hematol. 2019 Dec;110(6):654–664. doi:10.1007/s12185-019-02709-8.
   PubMed Web of Science ®Google Scholar
• Maiti A, DiNardo CD, Daver NG, et al. Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia. Blood Cancer J. 2021 Feb 1;11(2):25), doi:10.1038/s41408-021-00410-w.
   PubMed Web of Science ®Google Scholar
• The Menin Inhibitor SNDX-5613 (revumenib) Leads to Durable Responses in Patients (Pts) with KMT2A-Rearranged or NPM1 Mutant AML: Updated Results of a Phase (Ph) 1 Study. Program: oral and poster abstracts. Type: Oral. Session: 616. Acute myeloid leukemias: investigational therapies, excluding transplantation and cellular immunotherapies: relapsed/refractory AMLHematology disease topics & pathways: clinical trials, research, clinical research, drug development, therapies.
   Google Scholar
• First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia. https://clinicaltrials.gov/ct2/show/NCT04067336
   Google Scholar
• Schaefer EW, Loaiza-Bonilla A, Juckett M, et al. A phase 2 study of vorinostat in acute myeloid leukemia. Haematologica. 2009 Oct;94(10):1375–82. doi:10.3324/haematol.2009.009217.
   PubMed Web of Science ®Google Scholar
• Gojo I, Tan M, Fang HB, et al. Translational phase I trial of vorinostat (suberoylanilide hydroxamic acid) combined with cytarabine and etoposide in patients with relapsed, refractory, or high-risk acute myeloid leukemia. Clin Cancer Res. 2013 Apr 1;19(7):1838–51. doi:10.1158/1078-0432.CCR-12-3165.
   PubMed Web of Science ®Google Scholar
• He W, Zhao C, Hu H. Prognostic effect of RUNX1 mutations in myelodysplastic syndromes: a meta-analysis. Hematology. 2020;25(1):494–501. doi: 10.1080/16078454.2020.1858598.
   PubMed Web of Science ®Google Scholar
• Récher C, Beyne-Rauzy O, Demur C, et al. Antileukemic activity of rapamycin in acute myeloid leukemia. Blood. 2005;105(6):2527–2534. doi: 10.1182/blood-2004-06-2494.
   PubMed Web of Science ®Google Scholar
• Tan P, Tiong IS, Fleming S, et al. The mTOR inhibitor everolimus in combination with azacitidine in patients with relapsed/refractory acute myeloid leukemia: a phase Ib/II study. Oncotarget. 2016 Nov 29;8(32):52269–52280. doi:10.18632/oncotarget.13699.
   PubMedGoogle Scholar
• Taksin AL, Legrand O, Raffoux E, et al. High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group. Leukemia. 2007 Jan;21(1):66–71. doi:10.1038/sj.leu.2404434.
   PubMed Web of Science ®Google Scholar
• Pilorge S, Rigaudeau S, Rabian F, et al. Fractionated gemtuzumab ozogamicin and standard dose cytarabine produced prolonged second remissions in patients over the age of 55 years with acute myeloid leukemia in late first relapse. Am J Hematol. 2014 Apr;89(4):399–403. doi:10.1002/ajh.23653.
   PubMed Web of Science ®Google Scholar
• Stein EM, Walter RB, Erba HP, et al. A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia. Blood. 2018 Jan 25;131(4):387–396. doi:10.1182/blood-2017-06-789800.
   PubMed Web of Science ®Google Scholar
• Zhou S, Liu M, Ren F, et al. The landscape of bispecific T cell engager in cancer treatment. Biomark Res. 2021;9:38. doi:10.1186/s40364-021-00294-9.
   PubMed Web of Science ®Google Scholar
• Ravandi F, Walter RB, Subklewe M, et al. Updated results from phase I dose-escalation study of AMG 330, a bispecific T-cell engager molecule, in patients with relapsed/refractory acute myeloid leukemia (R/R AML). Journal of Clinical Oncology. 2020;38(15_suppl):7508–7508.
   Web of Science ®Google Scholar
• Moore PA, Zhang W, Jonah Rainey G, et al. Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma. Blood. 2011;117(17):4542–4551. doi:10.1182/blood-2010-09-306449.
   PubMed Web of Science ®Google Scholar
• Uy GL, Aldoss I, Foster MC, et al. Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia. Blood. 2021;137(6):751–762. doi: 10.1182/blood.2020007732.
   PubMed Web of Science ®Google Scholar
• Daver N. Phase I/II study of azacitidine (AZA) with venetoclax (VEN) and magrolimab (magro) in patients (Pts) with newly diagnosed (ND) older/unfit or high-risk acute myeloid leukemia (AML) and relapsed/refractory (R/R) AML. ASH. 2022. https://ash.confex.com/ash/2022/webprogram/Paper170188.html
   Google Scholar
• Schmid C, Labopin M, Nagler A, et al. Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT acute leukemia working party. J Clin Oncol. 2007;25(31):4938–4945.
   PubMed Web of Science ®Google Scholar
• Takami A, Yano S, Yokoyama H, et al. Donor lymphocyte infusion for the treatment of relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation: A retrospective analysis by the adult acute myeloid leukemia working group of the Japan society for hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2014;20(11):1785–1790. doi:10.1016/j.bbmt.2014.07.010.
   PubMed Web of Science ®Google Scholar
• Pizzitola I, Anjos-Afonso F, Rouault-Pierre K, et al. Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo. Leukemia. (2014);28(8):1596–1605. doi:10.1038/leu.2014.62.
   PubMed Web of Science ®Google Scholar
• Wang Q, Wang Y, Lv H, et al. Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient With relapsed and refractory acute myeloid leukemia. Mol Ther. 2015;23(1):184–191. doi:10.1038/mt.2014.164.
   PubMed Web of Science ®Google Scholar
• Deeren D, Maertens JA, Lin T, et al. First results from the dose escalation segment of the phase I clinical study evaluating cyad-02, an optimized non gene-edited engineered NKG2D CAR T-cell product, in relapsed or refractory acute myeloid leukemia and myelodysplastic syndrome patients. Blood . 2020;136(Supplement 1):36. doi: 10.1182/blood-2020-139667.
   PubMedGoogle Scholar
• Ganzel C,  Sun Z, Cripe LD, et al. Very poor long-term survival in past and more recent studies for relapsed AML patients: the ECOG-ACRIN experience. Am J Hematol. 2018;93:1074–1081.
   PubMed Web of Science ®Google Scholar
• Walter RB, Othus M, Burnett AK, et al. Resistance prediction in AML: analysis of 4601 patients from MRC/NCRI, HOVON/SAKK, SWOG and MD anderson cancer center. Leukemia. 2015 Feb;29(2):312–20. doi:10.1038/leu.2014.242.
   PubMed Web of Science ®Google Scholar
• Giles F, O'Brien S, Cortes J, et al. Outcome of patients with acute myelogenous leukemia after second salvage therapy. Cancer. 2005 Aug 1;104(3):547–54. doi:10.1002/cncr.21187.
   PubMed Web of Science ®Google Scholar
• Shahswar R, Beutel G, Klement P, et al. FLA-IDA salvage chemotherapy combined with a seven-day course of venetoclax (FLAVIDA) in patients with relapsed/refractory acute leukaemia. Br J Haematol. 2020;188:e11–e15. doi:10.1111/bjh.16268.
   PubMed Web of Science ®Google Scholar
• Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Guideline Name V.3.2022. © National Comprehensive Cancer Network, Inc. 202X. All rights reserved. Accessed [2/27/2023 11:23:30 AM]. To view the most recent and complete version of the guideline, go online to NCCN.org.
   Google Scholar
• Lee J-H, Joo Y-D, Kim H, et al. Randomized trial of myeloablative conditioning regimens: busulfan plus cyclophosphamide versus busulfan plus fludarabine. J Clin Oncol. 2013 Feb 20;31(6):701–9. doi:10.1200/JCO.2011.40.2362.
   PubMed Web of Science ®Google Scholar
• Hourigan CS, Karp JE. Minimal residual disease in acute myeloid leukaemia. Nat Rev Clin Oncol. 2013 Aug;10(8):460–71. doi:10.1038/nrclinonc.2013.100.
   PubMed Web of Science ®Google Scholar
• Puckrin R, Atenafu EG, Claudio JO, et al. Measurable residual disease monitoring provides insufficient lead-time to prevent morphologic relapse in the majority of patients with core-binding factor acute myeloid leukemia. Haematologica. 2020;106(1):56–63. doi:10.3324/haematol.2019.235721.
   Web of Science ®Google Scholar